Summary & Overview
HCPCS Level II J9075: Cyclophosphamide Injection, 5 mg
HCPCS Level II code J9075 identifies a 5 mg unit of cyclophosphamide administered by injection. This code is used to bill for the chemotherapeutic agent itself and is relevant across oncology, hematology, and other specialties that use alkylating agents. Nationally, accurate reporting of drug J-codes like J9075 matters for reimbursement, inventory management, and clinical registry tracking of chemotherapy utilization.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a national-level view of how J9075 is categorized and billed, common payer considerations, and the clinical contexts in which cyclophosphamide injections are typically used.
Readers will learn: the clinical description and typical sites of service for J9075; which major payers are relevant for coverage and billing scenarios; expected service line and administration settings; and where to find related coding nuances. The report also outlines common modifiers and implementation notes for billing workflows when data are available. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code J9075 represents injection, cyclophosphamide, not otherwise specified, 5 mg. This billing code denotes administration of the chemotherapeutic agent cyclophosphamide in a 5 mg unit.
Service type: Medication administration / Injectable chemotherapy
Typical site of service: Outpatient infusion center, hospital outpatient department, physician office, or infusion clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J9075 (injection, cyclophosphamide, not otherwise specified, 5 mg) is an adult oncology or rheumatology patient requiring intravenous or intramuscular administration of cyclophosphamide for malignancy or severe autoimmune disease. Example scenario: a 58-year-old female with newly diagnosed stage IIIB ovarian carcinoma is scheduled for combination chemotherapy including cyclophosphamide. Prior to administration, the oncology nurse verifies consent, current labs (complete blood count, renal and hepatic panels), premedication orders (antiemetic and hydration), and an appropriate venous access device. The pharmacy compounds the dose based on body surface area; the infusion is administered in an outpatient infusion center over the prescribed timeframe with monitoring for immediate hypersensitivity, nausea, myelosuppression, hemorrhagic cystitis risk, and fluid status. Documentation includes drug name and strength, quantity administered, lot number, route, site of administration, time, vitals, pre- and post-hydration, antiemetic use, and any adverse events. Typical monitoring and follow-up orders include periodic CBCs, urinalysis if hematuria risk, and oncology clinic follow-up to assess response and toxicity.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug or biological quantity discarded/not administered to any patient | When part of a single-dose vial remains unused and must be reported per payer rules for wastage tracking. |